Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) radiopharmaceuticals.

With more than 20 clinical trials underway worldwide (including partnered investigator-led studies), Telix’s core pipeline aims to address significant unmet medical needs in prostate, kidney, brain, and blood cancers as well as a range of hard to treat immunologic and rare diseases.

Telix’s lead product for prostate imaging Illuccix® has been approved in Australia, Canada, and the United States.